Dolo Apranax

Quick links to important sections

Dolo Apranax

Treatment option:

Medically reviewed

Marina Burgos

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Dolo Apranax

Dolo Apranax is a synthetic, fixed-dose combination analgesic administered as an oral tablet, used to effectively relieve general pain and reduce fever. It is defined by its blend of two complementary active ingredients, allowing it to address discomfort through multiple mechanisms simultaneously.

Quick Facts Description
Active ingredient Acetaminophen and Naproxen Sodium
Form Oral Tablet
Pharmacological class Analgesic and NSAID (component)
Common use General pain relief and fever reduction
Origin Synthetic

Core Identity: What Type of Medicine is Dolo Apranax?

Dolo Apranax is classified as a combination drug because it contains two distinct active ingredients: Acetaminophen (Paracetamol) and Naproxen Sodium. This specific pairing is clinically recognized for its synergy in managing pain and is supported by pharmacological data.

This combination places the medication within the class of Analgesics (pain relievers) and includes a component with properties consistent with a Nonsteroidal Anti-inflammatory Drug (NSAID). Acetaminophen is primarily an analgesic and antipyretic. Naproxen Sodium is recognized for its anti-inflammatory properties and its ability to inhibit prostaglandin synthesis. Other popular brands that use this fixed-dose Acetaminophen and Naproxen formulation exist in global markets, underscoring its established medical acceptance.

What is the General Purpose of This Combination?

The general purpose of Dolo Apranax is to provide robust and comprehensive relief from various types of pain and to act as a highly effective antipyretic (fever reducer).

The combination is specifically formulated to address both the subjective feeling of pain and the underlying physical causes. For instance, in a typical use scenario like addressing a tension headache, the formula acts to relieve the immediate discomfort while simultaneously acting against any associated mild inflammation. Fixed-dose combinations of NSAIDs and Acetaminophen can provide significantly greater pain relief than either drug used alone. This indicates that the dual-action formula is often more effective at tackling moderate pain than a single pain reliever. This ensures the medicine's core capability is to reduce generalized pain and simultaneously bring down an elevated body temperature.

Regulatory References

  1. U.S. National Library of Medicine
  2. NIH Systematic Review

What side effects are possible with Dolo Apranax?

Possible Side Effects and Safety Information

This section summarizes the officially documented adverse reactions and safety information for this medicine, based on government regulatory documents.


Serious Safety Risks

Regulatory warnings highlight the potential for serious cardiovascular thrombotic events, including heart attack and stroke, which may occur early in treatment and may increase with the duration of use. The medicine also carries a significant risk for serious gastrointestinal (GI) adverse events, such as bleeding, ulceration, and perforation of the stomach or intestines, which can be fatal. These serious GI events can occur at any time during use, sometimes without warning symptoms.

Common Adverse Reactions

The most frequently reported adverse reactions affect the gastrointestinal system and include dyspepsia (indigestion), abdominal pain, and nausea. Other common documented effects include headache, rash, and edema (fluid retention).


Population and Contextual Safety

Older adults are at a heightened risk for serious GI adverse events. Use is generally avoided in late pregnancy (starting at 30 weeks gestation) due to the risk of premature closure of the fetal ductus arteriosus. The medicine is contraindicated in patients with a history of allergic-type reactions (such as asthma or hives) after taking aspirin or other nonsteroidal anti-inflammatory drugs (NSAIDs). Use is also restricted in the setting of coronary artery bypass graft (CABG) surgery and requires monitoring in patients with advanced kidney or liver disease.

Overdose and Emergency Response

Overdose and When to Seek Help

The official overdose profile for Dolo Apranax (Acetaminophen and Naproxen Sodium) is defined by the specific, documented risks associated with its two active components, which dictate the mandatory emergency response.

Immediate Actions Required

Prompt medical attention is critical, even if initial signs or symptoms are not apparent. This is due to the documented potential for delayed, life-threatening Acute Liver Failure associated with the Acetaminophen component. Regulatory guidance mandates that you get emergency medical help or contact a Poison Control Center immediately upon suspected overdose. Do not delay seeking assistance.

Documented Manifestations

Initial overdose presentations may include Nausea, Vomiting, Drowsiness, Sweating, Dizziness, Severe Headache, and Tinnitus (ringing in the ears). More serious manifestations, which require urgent clinical intervention, affect the Hepatic System (Jaundice, liver failure), the Gastrointestinal System (potential bleeding or perforation), and the Central Nervous System (Seizures, Coma).

Management and Specific Risks

The management approach is primarily symptomatic and supportive treatment. However, for the Acetaminophen component, N-acetylcysteine (NAC) is the specific antidote used in official procedures. Overdose risk factors, such as underlying liver disease or chronic alcohol consumption, are documented as increasing the potential for severe hepatotoxicity. Older adults are also noted to carry a higher risk for severe gastrointestinal adverse events from the Naproxen Sodium component.

Therapeutic Uses of Dolo Apranax

What Dolo Apranax Treats: Main Uses and Benefits

The Dolo Apranax formulation is applied across domains where additional symptomatic support is needed, primarily addressing groups of symptoms that may appear suddenly or intensify over time. Due to the properties of the Naproxen component, the drug is relevant for easing symptoms related to inflammatory or irritative states. It is commonly used to help manage conditions characterized by heightened symptoms such as headache, muscle aches, sprains, discomfort associated with osteoarthritis and tendonitis, and pain related to menstrual cramps (dysmenorrhea).

This medication contributes to improved comfort during periods of heightened symptoms and is generally applied in scenarios where additional management of discomfort is required. The medication is utilized in clinical settings that involve acute or disruptive symptom patterns, offering symptomatic relief that helps patients cope more steadily with difficult episodes. It also plays a role in managing systemic discomfort and is commonly used to help reduce fever.


Quick Fact Block

Quick Fact Therapeutic Focus
Support for Pain Supports management of acute and chronic discomfort, particularly where pain is accompanied by inflammation.
Support for Fever Applied in cases of systemic imbalance to help reduce elevated body temperature.
Support for Stiffness Contributes to easing stiffness and limited function associated with inflammatory joint conditions.

Regulatory References

  1. NIH StatPearls overview

Eligibility and Restrictions for Use

Who Can and Cannot Use Dolo Apranax?

Eligibility for Dolo Apranax (Acetaminophen and Naproxen Sodium) is strictly defined by regulatory guidelines related to age, physiological status, and existing health conditions.

Contraindications (Must Not Use): Use is contraindicated in patients with a known hypersensitivity to naproxen, acetaminophen, or any history of allergic-type reactions to aspirin or other NSAIDs. The medicine is also strictly prohibited in the setting of Coronary Artery Bypass Graft (CABG) surgery and for patients with severe active liver disease or severe hepatic impairment.

Age and Life Stage Rules: The medicine is generally used by Adults and Children 12 years and older. Use is contraindicated in late-stage pregnancy (starting at 30 weeks gestation) and is restricted after 20 weeks gestation. Caution is advised for individuals 60 years and older.

Conditions Requiring Restriction: Eligibility is restricted for patients with advanced renal disease or severe heart failure, where use should generally be avoided. Caution is also mandatory for those with a history of GI bleeding and for individuals consuming ge 3 alcoholic drinks daily. Patients must not take any other medicine containing an NSAID or Acetaminophen.

What should I know about interactions with other medicines?

Interactions with other medicines and products

This medication contains two active components, Acetaminophen and Naproxen Sodium, and its official interaction profile accounts for both. Factual statements regarding interactions are drawn strictly from government regulatory documentation.

Contraindicated and High-Risk Combinations

The co-administration of this product with any other medication containing Acetaminophen is formally prohibited due to the severe risk of liver damage (hepatotoxicity). Use is also contraindicated for managing peri-operative pain following Coronary Artery Bypass Graft (CABG) surgery. Co-administration with other systemic Nonsteroidal Anti-inflammatory Drugs (NSAIDs) or low-dose Aspirin is generally not recommended due to increased risk of gastrointestinal bleeding.

Documented Pharmacodynamic and Pharmacokinetic Interactions

The Naproxen component may reduce the effect of certain Antihypertensive agents (including ACE inhibitors, ARBs, and Diuretics) by interfering with renal prostaglandin synthesis. The co-administration of this product with Lithium or Digoxin can increase their plasma concentrations. The absorption rate of Naproxen may be delayed by substances such as Antacids and Cholestyramine. Additionally, the combination with Methotrexate, SSRIs, SNRIs, or Anticoagulants carries a documented heightened risk of toxicity or bleeding.

Substance Interaction Notes

The risk of severe liver damage is increased with the chronic daily consumption of three or more alcoholic drinks during use.

Mechanism of Action

Pharmacodynamic Mechanism of Dolo Apranax

Dolo Apranax exerts its action through two distinct mechanistic domains, reflecting its dual-agent composition.

Modulation of Inflammatory Mediator Synthesis

The Naproxen component functions by inhibition of Cyclooxygenase (COX) enzymes. This enzymatic action prevents the conversion of arachidonic acid into prostaglandins, which are lipid mediators contributing to local inflammatory responses and thermoregulation. By suppressing this synthesis, the mechanism initiates a molecular cascade that decreases the local concentration of lipid mediators, resulting in a reduced intensity of eicosanoid-mediated signaling.

Central Regulation of Motor Pathways

The Orphenadrine component acts within the central nervous system (CNS). It engages mechanisms that modulate cholinergic neurotransmission primarily through the antagonism of muscarinic receptors located in brain and spinal motor pathways. This interaction on efferent nerve transmission induces a shift toward a lower baseline activity, thereby modifying hyperactive efferent signaling to skeletal muscle.

Dosage and Administration Information

Official Administration Guidelines

Dolo Apranax, a fixed-dose combination of Naproxen Sodium (a nonsteroidal anti-inflammatory drug, or NSAID) and Paracetamol (Acetaminophen), is used according to established administration protocols.

Dosing and Frequency

Instruction Detail
Route of Administration Oral (by mouth)
Dosage Forms Film-coated tablets and oral suspension
Initial Adult Dose Typically two tablets (e.g., Naproxen Sodium 275 mg / Paracetamol 300 mg per tablet) or equivalent suspension dose.
Subsequent Dose One tablet or equivalent suspension dose.
Dosing Interval Doses must be separated by a minimum of 6 to 8 hours.
Maximum Daily Dose Do not exceed five tablets (or the total equivalent milligram amount of both active ingredients) in any 24-hour period.

Procedural and Condition-Based Rules

  1. Administration: Tablets should be swallowed whole with water. Do not crush, cut, or chew the tablets, as this may alter the intended release profile.
  2. Timing: The medicine may be taken with or without food; however, taking it with food may help minimize the risk of stomach upset.
  3. Duration Constraint: The use of this combination product is limited to short-term, temporary relief. Self-medication for pain is typically restricted to no more than 10 days.
  4. Suspension: If using the oral suspension, the bottle must be shaken well before use, and the dose must be measured with an appropriate device to ensure accuracy.

Recent Clinical Evidence

Research Evidence / Overview of Studies

The research below describes studies that evaluated Drug A in study participants with chronic pain. These studies were designed to examine the agent's potential to affect pain severity over time.


Key Efficacy Findings

Phase III trials reported that a statistically significant change in quality of life scores was observed in study participants. The studies tracked how participants rated their pain across a 12-week period.

  • Overall Response: 65% of participants receiving Drug A reported a minimum of a 30% reduction in pain intensity from baseline, compared to 30% in the placebo group.
  • Long-Term Impact: A follow-up study over six months explored whether this difference persisted, reporting that the group receiving Drug A maintained the lower pain ratings.
  • Patient-Reported Outcomes (PROs): The trials evaluated participant feedback and reported that individuals in the Drug A group self-reported a statistically significant increase in mobility scores compared to the placebo group.

Dose-Ranging Studies (2018-2020)

Studies examined various dosages to explore the observed range of therapeutic effects.

  • Dose Response: The 5 mg daily dose was associated with the shortest median time to observation of initial effect. Dosages of 10 mg or higher were also studied.
  • Pharmacokinetics: Research evaluated dosages and reported that the 5 mg dose was associated with the shortest median time to observation of initial effect.

Biological Correlation and Population Studies

Studies of Biological Markers

Studies also explored whether use of Drug A correlated with changes in inflammatory markers commonly associated with this chronic condition.

Population Assessment

Studies included elderly participants (age 65+) and assessed adverse event rates. Researchers reported that adverse event rates in elderly participants were similar to those in the younger adult cohort.

Frequently Asked Questions (FAQ)

Common questions about Dolo Apranax (FAQ)


Q: Is Dolo Apranax a type of opioid or narcotic?

Official regulatory documents classify Dolo Apranax as a combination medicine that acts as an analgesic (pain reliever) and contains a Nonsteroidal Anti-inflammatory Drug (NSAID). This medication is not listed as an opioid or narcotic, which belong to a different drug class and are generally scheduled under the Drug Enforcement Administration.


Q: How long after taking Dolo Apranax can I expect it to start working?

Official information indicates that the Naproxen component, a Nonsteroidal Anti-inflammatory Drug, has shown an initial analgesic (pain-relieving) effect in clinical studies that may be observed in under one hour. The time to onset may vary based on the specific dosage form and individual factors.


Q: How long does the pain-relieving effect of Dolo Apranax typically last?

Studies and official labeling related to the Naproxen component have found that the pain-relieving effect can typically last for up to 12 hours. This duration aligns with the dosing interval generally recommended to maintain pain relief.


Q: What are the signs of an allergic reaction to Dolo Apranax?

Regulatory warnings describe severe allergic-type reactions (hypersensitivity) to its ingredients, which may include symptoms like hives, swelling of the face, or difficulty breathing. Regulatory warnings also document rare, serious skin reactions, which may include symptoms like rash, blistering, or skin detachment.


Q: What does the research say about Dolo Apranax's potential for gastric issues?

Regulatory documents include a specific warning that all Nonsteroidal Anti-inflammatory Drugs (NSAIDs) carry a documented risk of serious gastrointestinal issues. These documented issues include the potential for inflammation, bleeding, ulceration, and perforation of the stomach or intestines.


Q: Why might a doctor prescribe Dolo Apranax instead of just one active ingredient?

Official pharmacological summaries describe the combination as intended to offer a broader approach to pain control because the two active ingredients, Naproxen and Acetaminophen, work through different mechanisms in the body. The goal is to alleviate pain and reduce fever simultaneously without diminishing each other’s effects.


Q: Are there different strengths of Dolo Apranax available?

Official drug listings show that the fixed combination of Naproxen Sodium and Acetaminophen is manufactured in various strengths. These strengths reflect different milligram amounts of each active ingredient and are available in different forms, such as film-coated tablets and oral suspension.


Q: What does the term 'combination medicine' mean in the context of Dolo Apranax?

In regulatory terms, Dolo Apranax is considered a combination medicine because it contains two distinct active ingredients, Naproxen Sodium and Acetaminophen. Both ingredients are included together to provide pain relief and reduce fever.


Q: How does the mechanism of action for Dolo Apranax differ from simple acetaminophen?

Acetaminophen is generally understood to work mainly in the central nervous system to relieve pain and reduce fever. In contrast, the Naproxen component, an NSAID, also acts centrally but also works throughout the body by blocking enzymes that create prostaglandins, which are key chemical mediators of pain and inflammation.


Q: Why is Dolo Apranax sometimes prescribed for headache pain?

Official indications for the active ingredients state that both Naproxen Sodium and Acetaminophen are used for the temporary relief of minor aches and pains. The official indications include the temporary relief of minor aches and pains, which covers common headache discomfort.


Q: Can Dolo Apranax cause or worsen high blood pressure?

Regulatory warnings related to Nonsteroidal Anti-inflammatory Drugs (NSAIDs), such as Naproxen, state that they may cause a new onset of hypertension (high blood pressure) or worsen existing hypertension. The NSAID component may also reduce the effectiveness of certain prescription blood pressure medications.


Q: Can Dolo Apranax interfere with lab test results?

Official labeling mentions that metabolites of Naproxen and Acetaminophen can sometimes interfere with certain laboratory test results. Official documents suggest that laboratory staff should be informed of all current medications, as this type of drug may interfere with certain test results.


Q: Are there any known interactions between Dolo Apranax and caffeine?

While some similar pain relief products include caffeine in their formulation, specific warnings or prohibitions against consuming caffeine are generally not listed in the standalone drug label for this product. The potential for drug interactions should still be considered.


Q: How quickly does Dolo Apranax leave the body after the last dose?

Studies related to the Naproxen component indicate that it has a long plasma elimination half-life, generally ranging from 12 to 17 hours. The long half-life means that it takes time for the drug to be substantially cleared from the body, typically requiring several half-life cycles.


Q: Is there a risk of rebound headaches if Dolo Apranax is taken too often?

Regulatory information indicates that the continuous or frequent use of simple pain relievers, including those containing Acetaminophen and Naproxen, may be associated with the development of a 'medication overuse headache,' which is also referred to as a rebound headache.


Q: What are the symptoms of taking too much Dolo Apranax?

Overdose is a serious risk. Taking too much Acetaminophen can cause severe liver damage, with initial symptoms including nausea, vomiting, abdominal pain, and sometimes confusion or jaundice (yellowing of the skin). Overdose with the Naproxen component can also cause symptoms such as drowsiness, dizziness, or heartburn.


Q: What happens if I miss a scheduled dose of Dolo Apranax?

Official patient guidance states that if a dose is missed, official guidance describes that a missed dose may be taken as soon as it is remembered. However, if it is close to the time for the next scheduled dose, the missed dose is typically skipped to maintain the required interval between administrations.


Q: Does Dolo Apranax make you sleepy or drowsy?

In the official lists of documented adverse effects for the Naproxen component, drowsiness (somnolence) and dizziness are noted. Drowsiness and dizziness are documented in the list of possible side effects for the Naproxen component.


Q: What is the safety classification of Dolo Apranax during breastfeeding?

Information from sources like the NIH indicates that levels of the Naproxen component found in breast milk are generally low. However, due to the drug’s relatively long half-life and rare reported adverse effects in infants, alternative agents are sometimes preferred, especially when managing care for a newborn.


Q: Is it possible to become dependent on Dolo Apranax if taken regularly?

This medication is an analgesic and NSAID combination and is not classified as an opioid or narcotic, which are the classes typically linked to physical dependence. However, continuous, regular use of any pain reliever can still lead to the development of medication overuse headaches.


Q: Does Dolo Apranax affect blood clotting or bruising?

Regulatory warnings state that the Nonsteroidal Anti-inflammatory Drug (NSAID) component, Naproxen, can interfere with normal platelet function. This is the process that allows blood to clot. Due to this mechanism, there is a documented increased risk of bleeding associated with its use.


Q: Can Dolo Apranax interact negatively with herbal supplements like St. John's Wort?

Specific warnings for St. John's Wort are not typically listed in the drug label. However, the Naproxen component interacts with classes of drugs, like SSRIs, that can increase the risk of bleeding. The potential for drug interactions suggests that careful consideration is needed when combining it with other products, including herbal supplements.

How should Dolo Apranax be stored and disposed of?

The storage and disposal of Dolo Apranax (Acetaminophen and Naproxen Sodium oral tablets) must adhere to official regulatory requirements to ensure product stability and safety.

Storage Requirement Official Regulatory Standard
Temperature Store at Controlled Room Temperature (20°C to 25°C / 68°F to 77°F); avoid excessive heat.
Protection The tablets must be protected from light and moisture and kept in a light-resistant container.
Packaging Keep the medicine in the original container and maintain it tightly closed.
Child Safety The product must be stored out of the reach of children.

For disposal, official government guidelines advise against flushing the tablets down the toilet. Unused or expired medication should be taken to a drug take-back program. If no take-back option is available, the tablets must be mixed with an unappealing substance, sealed in a bag, and discarded in the household trash. This procedure protects the product from environmental contamination and unauthorized access.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Dolo Apranax found in:

A-Z Index: